Sunepitron
Sunepitron is a pharmacological compound that was developed as a potential treatment for depression and anxiety. It is classified as a serotonin and norepinephrine reuptake inhibitor (SNRI), which means it works by increasing the levels of these two neurotransmitters in the brain.
History[edit | edit source]
Sunepitron was first synthesized in the late 1980s by the pharmaceutical company Wyeth. It was initially developed as a potential treatment for major depressive disorder (MDD) and generalized anxiety disorder (GAD). However, despite showing promise in early clinical trials, the development of Sunepitron was discontinued in the late 1990s due to concerns about its safety and efficacy.
Pharmacology[edit | edit source]
As an SNRI, Sunepitron works by inhibiting the reuptake of serotonin and norepinephrine in the brain. This results in increased levels of these neurotransmitters in the synaptic cleft, which can help to alleviate the symptoms of depression and anxiety.
Sunepitron is also a partial agonist at the 5-HT1A receptor, which is thought to contribute to its anxiolytic effects. However, the exact mechanism of action of Sunepitron is still not fully understood.
Clinical Trials[edit | edit source]
In the early 1990s, Sunepitron underwent several Phase II clinical trials for the treatment of MDD and GAD. These trials showed that Sunepitron was generally well-tolerated and had a similar efficacy to other SNRIs. However, some patients experienced side effects such as nausea, dizziness, and insomnia.
Despite these promising results, the development of Sunepitron was discontinued in the late 1990s. This was due to concerns about the drug's safety profile, as well as doubts about its efficacy compared to other available treatments.
Current Status[edit | edit source]
As of 2021, Sunepitron is not currently approved for use in any country. However, it is still occasionally used in research settings, particularly in studies investigating the pharmacology of SNRIs and 5-HT1A receptor agonists.
See Also[edit | edit source]
- Serotonin-norepinephrine reuptake inhibitor
- 5-HT1A receptor
- Major depressive disorder
- Generalized anxiety disorder
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
